ScreenPoint's $16M Fund Fuels AI's New Role in Breast Cancer Care

NIJMEGEN, Netherlands – April 17, 2026 – ScreenPoint Medical, a company at the vanguard of artificial intelligence in breast imaging, has secured $16 million in new financing, signaling strong investor confidence in AI's expanding role in healthcare. The funding round includes $14 million from long-term partners Insight Partners and Siemens Healthineers, supplemented by $2 million in non-dilutive research grants.

The capital injection arrives on the heels of a series of landmark clinical studies that provide powerful validation for the company's technology. It is earmarked to accelerate global expansion and fuel the development of a new generation of AI tools designed to create a more personalized and precise approach to breast cancer care, from early detection to treatment. With its Transpara® Breast AI already deployed in over 30 countries and having analyzed more than 12 million mammograms, the Dutch firm is solidifying its position as a dominant force in a rapidly evolving market.

The Clinical Proof: AI That Detects More and Reduces Burden

The foundation of investor confidence in ScreenPoint Medical is built not on promises, but on a growing mountain of clinical evidence. Recent publications in top-tier medical journals have moved the conversation about AI in radiology from theoretical potential to proven practice.

The most significant of these is the final analysis of the Mammography Screening with Artificial Intelligence (MASAI) trial, published in The Lancet. As the first randomized controlled trial of its kind, MASAI's findings are pivotal. The study demonstrated that using Transpara AI to support radiologists resulted in "consistently favourable outcomes compared with standard double reading." The AI-supported screening not only showed a 29% improvement in cancer detection but also led to a staggering 44% reduction in the mammogram reading workload for radiologists, a critical benefit in an era of workforce shortages.

Further research published in Nature Medicine explored the more futuristic concept of "autonomous" AI. The prospective study showed that Transpara could potentially and safely triage up to 63.6% of screening mammograms identified as low-risk, freeing radiologists to focus their expertise on more complex cases. While the company notes this application is currently investigational, it paints a clear picture of a future where AI handles the routine, allowing human experts to perform at the top of their license.

"ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging," said Dr. Robert Epstein, MD, FACR, a Health Care Senior Advisor at Insight Partners. "The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level."

The "Smart Money" Doubles Down on a Market Leader

The $16 million infusion is more than just operational fuel; it's a strategic endorsement from two of the most influential players in software and healthcare technology. Both Insight Partners, a global software investor, and Siemens Healthineers, a medical technology giant, are existing investors, having previously backed the company in a $28 million Series C round in 2021. Their continued participation signifies a long-term commitment and a belief in ScreenPoint's market strategy and technological roadmap.

This sustained financial backing is crucial in the capital-intensive field of medical AI, where the path from algorithm development to regulatory approval and clinical adoption is long and arduous. For ScreenPoint, it provides the stability to pursue ambitious research and development goals while simultaneously scaling its commercial operations.

"This investment endorses our strategy and our shared success," said Pieter Kroese, CEO of ScreenPoint Medical, in a statement. "We are well positioned to scale globally and accelerate the development of solutions that make care personal and powerful."

Alexandra Krumbügel, Head of Product Line Women's Health, X-ray Products at Siemens Healthineers, echoed this sentiment, adding, "Our continued investment reflects our strong conviction that AI will play a defining role in the future of breast imaging. This collaboration is driven by a shared focus on advancing breast cancer innovation."

From Algorithm to Clinic: Navigating the Path Forward

While the headlines focus on the funding and trial results, ScreenPoint's strategy involves navigating the complex regulatory landscape and methodically building out its product suite. The company's core product, Transpara, already holds significant regulatory approvals, including FDA 510(k) clearance in the United States and a CE Mark in Europe for both 2D and 3D mammography.

The latest version, Transpara 2.1, introduces a market-first temporal comparison feature, which allows the AI to analyze suspicious areas by comparing them against up to three prior mammograms from the past six years. This capability mimics the workflow of an expert radiologist, providing deeper context and potentially reducing false positives.

The company is also pushing the boundaries of risk assessment. A study in npj Digital Medicine showed its image-based risk algorithm outperformed competing models from iCAD, Mirai, and even Google at predicting five-year cancer risk. Bolstering this effort, ScreenPoint recently acquired Danish firm Biomediq A/S to integrate its advanced mammographic texture biomarkers, further enhancing the predictive power of its risk models. While these advanced risk prediction algorithms are still listed as investigational, they represent the next frontier for the company and the field.

To solidify its foothold in the crucial U.S. market, ScreenPoint is participating in the landmark $16 million PRISM trial. This pragmatic study, funded by the Patient-Centered Outcomes Research Institute (PCORI), will evaluate Transpara's effectiveness across the United States, providing real-world evidence essential for widespread adoption and reimbursement. This strategic move demonstrates a clear understanding that clinical validation must be tailored to specific healthcare systems and patient populations to achieve true market leadership. The trial will be instrumental in bridging the gap between European success and deep penetration into the American healthcare system.